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We used cutaneous delayed-type hypersensitivity responses, a powerful in vivo measure of cell-mediated
immunity, to evaluate the relationships among cell-mediated immunity, AIDS, and polymorphisms in CCR5,
the HIV-1 coreceptor. There was high concordance between CCR5 polymorphisms and haplotype pairs that
influenced delayed-type hypersensitivity responses in healthy persons and HIV disease progression. In the
cohorts examined, CCR5 genotypes containing -2459G/G (HHA/HHA, HHA/HHC, HHC/HHC) or -2459A/A
(HHE/HHE) associated with salutary or detrimental delayed-type hypersensitivity and AIDS phenotypes,
respectively. Accordingly, the CCR5-D32 allele, when paired with non-D32-bearing haplotypes that correlate
with low (HHA, HHC) versus high (HHE) CCR5 transcriptional activity, associates with disease retardation or
acceleration, respectively. Thus, the associations of CCR5-D32 heterozygosity partly reflect the effect of the non-
n32 haplotype in a background of CCR5 haploinsufficiency. The correlations of increased delayed-type
hypersensitivity with -2459G/G-containing CCR5 genotypes, reduced CCR5 expression, decreased viral
replication, and disease retardation suggest that CCR5 may influence HIV infection and AIDS, at least in part,
through effects on cell-mediated immunity.
Significant inter-individual variability in cell-mediated
immunity (CMI) may underlie differences in suscepti-
bility to diseases. Although in vitro data and studies in
knockout mice have identified many host factors that
influence CMI, informative model systems are generally
unavailable for evaluating how these factors may
influence CMI status in vivo in humans.
Delayed-type hypersensitivity (DTH) skin test re-
activity, a typical in vivo manifestation of CMI [1],
correlates strongly with T cell responses in vitro [2, 3].
Because cutaneous DTH responses may serve as an in-
formative model system to assess functional immune
status in vivo, we evaluated the associations of CCR5
genotypes with this correlate of CMI in healthy persons
and then compared them with the impact of these CCR5
variations on AIDS status. Our primary rationale was
that DTH status of HIV-infected patients predicts
clinical outcome, both before [2, 4] and after [5] initi-
ation of antiretroviral therapy, and correlates with res-
toration of immune responsiveness [6]. Second, there
is a strong association of polymorphisms in CCR5,
the major HIV-1 coreceptor, with HIV and AIDS
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phenotypes [reviewed in [7]]. Homozygosity for a 32–base pair
(bp) deletion (D32) in CCR5 results in complete loss of CCR5
expression and resistance to HIV acquisition [7]. In addition,
single nucleotide polymorphisms (SNPs) in the CCR5 promoter
and CCR5 haplotypes bearing distinct combinations of SNPs
associate with particular phenotypes, including transcriptional
activity [8], CCR5 surface levels [9–11], HIV infectivity ex vivo
[10, 12], and HIV susceptibility [7,13–15]. Third, because both
DTH [1] and CCR5 [16, 17] impact on Th1 responses and
CCR5 influences overall T cell immunity [discussed in [17]], it
was highly plausible that CCR5 would affect CMI in vivo in
humans, just as it does in murine models [4].
In support of this concept, we found previously in healthy
persons that CCR5 haplotype pairs associated with low DTH
responses to the neo-antigen keyhole limpet hemocyanin (KLH)
or the recall antigen purified protein derivative (PPD) were
similar to those that associated with disease acceleration in HIV-
infected adults [4]. However, these inferences were based on
pooling CCR5 genotypes of HIV-uninfected persons into 2
groups–those associating with DTH responses that were lower
than versus equal to or greater than the average DTH response
found in the overall cohort–and then demonstrating that these 2
categories of DTH-influencing CCR5 genotypes correlated with
HIV disease phenotypes [4]. This approach of pooling DTH-
influencing CCR5 genotypes was useful for increasing statistical
power, but it precluded identification of the specific poly-
morphism(s) or CCR5 haplotype pairs that have major influ-
ences on both CMI and HIV status.
The importance of defining specific genetic variations is un-
derscored by reassessing the associations of CCR5 levels and
CCR5-D32 heterozygosity. CCR5 density can differ by as much
as 20-fold on the surface of T cells from individuals lacking the
CCR52D32 mutation, many of whom have levels similar to
those of D32 heterozygotes [18, 19]. Similarly, surface density
varies significantly among CCR52D32 heterozygotes [19, 20].
These variations have clinical implications, because some HIV-
uninfected persons who are highly exposed to HIV have CCR5
levels comparable to CCR52D32 heterozygotes [19, 21]. Thus,
CCR5 genotypes lacking CCR5-D32 may contribute to low
CCR5 expression and a protective HIV and AIDS phenotype.
Moreover, the associations of CCR52D32-containing genotypes
with HIV and AIDS may partly reflect the effects of the func-
tional non–D32 CCR5 haplotype.
We previously used linkage disequilibrium patterns and an
evolutionary approach to classify polymorphisms in CCR2
(V64I) and CCR5 (D32 and promoter SNPs) into CCR5 hap-
lotypes designated as HHA to HHG*2 [8, 14]. CCR5-HHG*2
and CCR5-HHF*2 haplotypes bear the CCR5-D32 and CCR2-
64I polymorphisms, respectively [14]. These CCR5 haplotypes
have striking population-specific distributions [22] and associ-
ate with contrasting phenotypes relevant to HIV and AIDS.
CCR5-HHA, the ancestral haplotype [8], is prevalent among
persons of African descent [14, 22]. CCR5-HHA-specific regu-
latory and/or promoter sequences correlate with the lowest
transcriptional activity [8]. CCR5-HHA associates with HIV
disease retardation in African-Americans, whereas CCR5-HHC
does so among European-Americans [14]. By contrast, CCR5-
HHE-specific regulatory and/or promoter sequences associate
with the highest transcriptional activity [8], surface expression
[9], and HIV and AIDS susceptibility [7,13–15].
Given these CCR5 haplotype-phenotype relationships, it was
conceivable that pairing of the D32-containing HHG*2 haplo-
type with HHE would associate with detrimental HIV and AIDS
phenotypes, whereas its pairing with HHA, HHC, or HHF*2
would associate with protective HIV and AIDS phenotypes.
Indeed, the existence of these 2 categories of CCR5-D32–
containing genotypes is supported by 3 lines of evidence. First,
Kawamura et al [12] found that Langerhans cells bearing HHE/
HHG*2 exhibited increased ex vivo susceptibility to productive
HIV R5 infection, compared with all other HHG*2-containing
genotypes. Second, HHE/HHG*2 is associated with HIV disease
acceleration and increased risk of acquisition of HIV [15]. Fi-
nally, Tang et al [23] reported that HHA/HHG*2 and HHF*2/
HHG*2 accounted for much of the HHG*2 haplotype-related
effects on HIV disease, whereas, we [14, 15], Martin et al [13],
and Hladik et al [24] found that HHC/HHG*2 (designated P4/
D32 in [13]) associated with favorable HIV disease phenotypes.
This reappraisal of the associations of CCR5-D32 heterozy-
gosity highlights the complexity of the CCR5 genotype-HIV
phenotype relationships and the importance of accounting for
both CCR5 haplotypes when evaluating the associations of
CCR5 polymorphisms. Failure to do so may obscure CCR5
genotype-phenotype relationships and preclude identification of
the full repertoire of CCR5-dependent genetic factors that
correlate with phenotypes, such as CMI and susceptibility to
HIV and AIDS. Therefore, to evaluate the full range of mecha-
nisms by which CCR5 may influence HIV pathogenesis, we
sought here to identify the specific CCR5 genetic determinants
that associate with both CMI and AIDS status. To ensure robust
analyses, we evaluated 2 distinct cohorts of HIV-infected chil-
dren and 2 separate cohorts of normal individuals in whomCMI
status was assessed by cutaneous DTH responses to either KLH
or PPD.
MATERIALS AND METHODS
The primary cohort for evaluation of the association of CCR5
genotypes with DTH responses comprised a previously de-
scribed cohort of 206 healthy HIV-uninfected adults from
Australia in whom cutaneous DTH responses to the neoantigen
KLH were assessed [4, 25]. In brief, the cohort was comprised of
110 male participants and 96 female participants, with 137
(66%), 66 (32%), and 3 (1%) being Caucasian, Asian, and un-
known ethnicity, respectively. The methods for assessment of
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DTH responses to KLH after presensitization were reported [4,
25]. For replication, we investigated a previously described
Colombian cohort of 172 persons in whom the tuberculin skin
test (purified-protein derivative [PPD]) was applied [4]. As
previously [4], because a low DTH response to PPD could be
attributable to lack of prior exposure to either Mycobacterium
tuberculosis or vaccination with bacilli Calmette-Guerin, genetic
association studies were limited to those in whom the PPD skin
test exhibited >10 mm of induration (n 5 85).
The primary cohort for evaluation of the associations of
CCR5 genotype with HIV and AIDS phenotypes comprised 178
perinatally infected Ukrainian children whose characteristics
have been reported elsewhere [26]. For replication purposes, we
also evaluated a previously described cohort of 347 HIV-infected
Argentinean children [15]. The definition of AIDS used in both
pediatric cohorts is the 1993 Centers for Disease Control and
Prevention set of criteria for children. CCR5 genotypes were
determined as described elsewhere [14, 15].
DTH responses by CCR5 genotypes were compared by
Kruskal-Wallis and Mann-Whitney tests, and for the Australian
cohort, the associations are reported for all participants and for
the subset of European descent. The association of CCR5 gen-
otypes with rate of disease progression to AIDS was assessed by
Kaplan-Meier survival analyses, log-rank, Wilcoxon tests, and
Cox proportional hazards modeling. All statistical analyses were
conducted using Stata, version 10 (StataCorp).
RESULTS
CCR5 SNPs and Haplotypes
The composition of CCR2-CCR5 haplotypes is such that
they can be dichotomized into 2 broad categories: CCR5-
HHA, -HHB, -HHC and -HHD each bear 22459G/22135T,
whereas haplotypes HHE to HHG*2 bear 22459A/22135C
(Figure 1; [8, 14]). Because there is a strong linkage disequilib-
rium pattern between these 2 SNPs, hereafter we refer only to the
polymorphism at 22459. First, we determined associations at
the level of this SNP (22459), and then for the aforementioned
reasons, we undertook a systematic approach to identifying
the specific CCR5 haplotype pairs (Table 1) that bear -2459G
and/or -2459A that associate with both DTH and AIDS status.
Associations of CCR5 2A2459G
In healthy Australians, possession of –2459G/A and –2459A/A,
compared with CCR5 –2459G/G, associated with lower DTH
responses to KLH (Figure 2A; P , .05 for comparisons of G/G
versus either G/A or A/A, except for the comparison of G/G vs A/
A in all persons, which was P 5 .067). In HIV-infected Ukrai-
nian children, possession of –2459A/A-containing genotypes
associated with a significantly faster disease course, compared
with genotypes bearing –2459G/A or –2459G/G (Figure 2B). The
latter associations of 22459G/G reflects the combined effects of
3 CCR5 genotypes (HHA/HHA, HHC/HHC, and HHA/HHC)
(Table 1), suggesting that these genotypes that lacked CCR5-D32
(HHG*2) or CCR2-64I (HHF*2) associated with both increased
DTH and disease retardation. In subsequent analyses, when
possible, we compared the strength of the associations of other
CCR5 genotypes with the strengths of these salutary CCR5
22459G/G–containing genotypes.
Association of CCR5 HHE-Containing Genotypes with DTH/AIDS
Status
Consistent with their low prevalence in Europeans, HHB and
HHD haplotypes were infrequent in the cohorts we evaluated
(Table 1). Thus, the slow HIV disease course associated
with 22459G/A-containing genotypes in Ukrainian children
(Figure 2B) is a reflection of CCR5 haplotype pairs that bear
a22459G-containing haplotype (HHA orHHC) and a22459A-
containing haplotype (HHE to HHG*2) (Figure 1 and Table 1).
Figure 1. CCR5 gene structure, polymorphisms, and haplotypes. The
schema on the top depicts the CCR5 gene structure with Pr1 and Pr2
referring to CCR5 promoters 1 and 2, respectively [8]. Exons (Ex) 1 and 2
are the 5#-untranslated exons of CCR5, whereas exon 3 contains the open
reading frame of CCR5 [8]. Upstream of the CCR5 gene is the CCR2 gene.
On the basis of the linkage disequilibrium patterns between the
polymorphisms in the coding (D32) and noncoding (promoter) region of
CCR5 and the coding polymorphism (V64I) in CCR2, we previously used an
evolutionary-based strategy to generate the CCR5 human haplogroups
(HH) shown below the CCR5 gene structure [8]. These CCR5 human
haplogroups are designated as HHA to HHG*2, with HHF*2 and HHG*2
denoting the haplotypes that bear the CCR2-64I and CCR5-D32
polymorphisms, respectively. Because of its similarity to the chimpanzee
CCR5 sequence, the human CCR5 HHA haplotype is classified as the
ancestral CCR5 haplotype [8]. Nucleotide variations relative to the
ancestral sequence are shown in bold and bracketed. The various CCR5
numbering systems used in the literature are denoted below the
haplotype descriptions. Numbering system 1 is based on GenBank
accession numbers AF031236 and AF031237; numbering system 2 is
based on GenBank accession number U95626. Numbering system 3 is the
numbering system in which the first nucleotide of the CCR5 translational
start site is designated as 11 and the nucleotide immediately upstream
as -1 and is the nomenclature adopted previously [8]. rs numbers are
indicated at the bottom most row.
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Similarly, 22459A/A-containing genotypes are the conflation of
several CCR5 haplotype pairs (Table 1). Therefore, we next
evaluated the influence of specific 22459A/A- or 22459G/A-
containing genotypes on DTH and AIDS status.
In both the healthy Australians and HIV-infected Ukrainians,
the most common22459A/A-containing genotypes were HHE/
HHF*2, HHE/HHE, and HHE/HHG*2 (Table 1). The hierarchy
(increased to decreased) of the association of these genotypes
with DTH responses was HHE/HHF*2 to HHE/HHE to HHE/
HHG*2 (Figure 2C). Remarkably, this was similar to the hier-
archy observed for HIV disease course (slower to faster): HHE/
HHF*2 to HHE/HHE to HHE/HHG*2 (Figure 2D). Compared
with persons who had HHE/HHF*2, those bearing HHE/
HHG*2 had a nearly 4-fold (relative hazard, 4.70; 95% confi-
dence interval [CI], 1.50–14.8; P 5 .008) faster rate of pro-
gression to AIDS (Figure 2D).
CCR5 D32-Containing Genotypes and DTH/AIDS Status
We next evaluated the associations of CCR5-D32 initially on
the basis of the presence of the CCR5-D32 (HHG*2) mutation
(Figure 3A-B) and then at the level of specific D32-containing
genotypes (Figure 3C-F). The 22459G/G genotypes (HHA/
HHA, HHC/HHC, or HHA/HHC) (Table 1) associated with
higher DTH responses than did genotypes that contained the
HHG*2 (D32) haplotype (Figure 3A). In addition, HHG*2-
containing genotypes did not associate with a slow disease
course (Figure 3B). Because the HHE haplotype and HHE/HHE
genotype associate with increased transcriptional activity [8] and
accelerated disease course [7,13–15], respectively, we next
determined whether the associations of HHG*2-containing
genotypes differed depending on whether HHE comprised the
partner haplotype. Although HHE/HHG*2 and the other
HHG*2-containing genotypes had similar DTH responses
(Figure 3C), HHE/HHG*2 associated with a markedly faster rate
of disease course than did other HHG*2-containing genotypes
(Figure 3D). The common D32-containing genotypes, although
associated with similar DTH responses (Figure 3E), associated
with contrasting rates of disease progression, exhibiting a
hierarchy of (slow to fast disease): HHC/HHG*2 to other
HHG*2-containing genotypes to HHE/HHG*2 (Figure 3F).
CCR5 HHF*2-Bearing Genotypes with DTH and AIDS Status
Figure 2D shows that HHE/HHF*2 associated with a slow dis-
ease course, and Figure 4A shows that HHE/HHF*2 and
22459G/G-containing genotypes associated with comparably
high DTH responses (Figure 4A) and similar disease courses
(Figure 4B). Stratification of HHF*2-bearing genotypes revealed
that although HHE/HHF*2 associated with significantly stron-
ger DTH responses (Figure 4C), its association with a slower
disease course did not reach statistical significance (Figure 4D).
Replication of A22459G Genotypes Effects on DTH Status
CCR5 22459G/G, G/A, and A/A genotypes associated with
a step-wise decrease in DTH responses to PPD (Figure 5A),
indicating that 22459G/G and 22459A/A associated with high
and low DTH responses to both KLH (Figure 2A) and PPD
(Figure 5A). Because of the consistent association of HHE/HHE
with accelerated HIV disease course in multiple cohorts [7,13–
15], we stratified 22459A/A-bearing genotypes into HHE/HHE
versus all others (Figure 1 and Table 1). Figure 5B shows that
22459G/G-containing genotypes and HHE/HHE associate with
the maximal and least DTH responses to PPD, respectively.
Figure 2. Association of CCR522459G/G,22459G/A and22459A/A-
containing genotypes with DTH responses to KLH in HIV-uninfected
Australians and rates of progression to AIDS in HIV-infected Ukrainian
children. These 2 cohorts are the primary cohorts used for analyses of the
associations of CCR5 genotypes with DTH and AIDS status. A and C, Box
and whisker plots (boxplots) depicting the median and upper and lower
quartiles of the DTH responses in the HIV-uninfected Australians with
genotypes containing CCR5 22459G/G (green), 22459G/A (blue), and
22459A/A (red) (these genotypes are indicated at the bottom of the
panels). Box plots are shown for all participants. Significance values for
all participants and the Caucasians in the Australian cohort are shown on
the top. In the boxplots, the horizontal line within the box represents the
median, with whiskers representing the maximum and minimum values,
and the outliers are represented by black dots. B and D, Kaplan-Meier
plots for time to AIDS (1993 Centers for Disease Control and Prevention
criteria) for persons with genotypes containing CCR5 22459G/G (green
plot), 22459G/A (blue plot), and 22459A/A (red plot). The boxplots and
Kaplan-Meier plots are color-coded to indicate similarity in the genotypes
studied for their association with DTH responses and rates of disease
progression. In panels C and D, E/F*2, E/E and E/G*2 refer to HHE/HHF*2,
HHE/HHE, and HHE/HHG*2, respectively, with HHF*2 and HHG*2
reflecting CCR5 haplotypes that bear the CCR2-64I and CCR5 D32
polymorphisms, respectively.
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Replication of A22459G Genotypes Effects on AIDS
In HIV-infected Argentinean children, CCR5 22459G/G, G/A
and A/A genotypes associated with a step-wise increase in the
rate of disease progression, and consistent with the results shown
in Figure 2B for HIV-infected Ukrainian children, 22459G/G-
and 22459A/A-containing genotypes associated with maximal
disease retardation and acceleration, respectively (Figure 6A).
Also consistent with the results depicted in Figure 3B, in Ar-
gentinean children CCR5-D32 (HHG*2), heterozygosity associ-
ated with an accelerated disease course, compared with22459G/
G-containing genotypes (relative hazard, 1.69; 95% CI, .95 –
3.01; P: .073) (Figure 6B). Finally, mirroring the results shown
in Figure 3F, in Argentinean children with CCR5-D32 hetero-
zygosity, the accelerated disease course was also attributable
mainly to HHE/HHG*2, because CCR5-D32 genotypes that
were not HHE/HHG*2 associated with disease retardation
(Figure 6C).
DISCUSSION
We identified specific CCR5 SNPs and genotypes that associated
with cutaneous DTH responses to 2 distinct antigens (KLH and
Table 1. Distribution of CCR5 haplotype pairs (genotypes) among study participants
HIV-infected children HIV-uninfected adults
Ukraine Argentina
Australia
(DTH-KLH)
Colombia
(DTH-PPD)
Primary
cohort
Replication
cohort
Primary
cohort
Replication
cohort
G–2459Aa Haplotype pairs No. (%) No. (%) No. (%) No. (%)
G/G HHA/HHC 13 (7.42) 15 (4.32) 21 (10.24) 5 (5.88)
HHC/HHC 12 (6.85) 35 (10.09) 47 (22.92) 6 (7.05)
HHA/HHA 4 (2.28) 1 (.29) 2 (.97) 1 (1.17)
HHB/HHC - 1 (.29) - 1 (1.17)
HHC/HHD - 3 (.86) - 3 (3.52)
Total 29 (16.57) 55 (15.85) 70 (34.14) 16 (18.82)
G/A HHC/HHE 24 (13.7) 92 (26.51) 40 (19.51) 19 (22.35)
HHA/HHE 22 (12.5) 9 (2.59) 3 (1.46) 2 (2.35)
HHC/HHF*2 11 (6.28) 30 (8.65) 15 (7.31) 7 (8.24)
HHC/HHG*2 10 (5.71) 3 (.86) 9 (4.39) -
HHA/HHF*2 6 (3.42) 9 (2.59) 5 (2.43) 2 (2.35)
HHA/HHG*2 6 (3.42) 2 (.58) 1 (.48) -
HHC/HHG*1 4 (2.28) 11 (3.17) 6 (2.97) 2 (2.35)
HHA/HHG*1 1 (.57) - 2 (.97) -
HHC/HHF*1 - 12 (3.46) - 1 (1.17)
HHD/HHF*2 - 3 (.86) - 1 (1.17)
HHD/HHE - 1 (.29) - -
HHA/HHF*1 - 2 (.58) - -
Total 84 (48.00) 174 (50.14) 81 (39.51) 34 (40.00)
A/A HHE/HHF*2 20 (11.4) 23 (6.63) 16 (7.80) 10 (11.76)
HHE/HHE 14 (8.00) 41 (11.82) 16 (7.80) 6 (7.06)
HHE/HHG*2 13 (7.42) 13 (3.75) 7 (3.41) 1 (1.17)
HHE/HHG*1 5 (2.85) 14 (4.03) 2 (.97) 3 (3.53)
HHF*2/HHF*2 4 (2.28) 8 (2.31) 5 (2.43) 6 (7.06)
HHF*2/HHG*2 4 (2.28) 1 (.29) 3 (1.46) 1 (1.17)
HHF*2/HHG*1 1 (.57) 4 (1.15) 1 (.48) 3 (3.53)
HHG*1/HHG*1 1 (.57) - - 1 (1.17)
HHG*1/HHG*2 - 4 (1.15) 1 (.48) 1 (1.17)
HHF*1/HHF*2 - - 1 (.48) -
HHG*2/HHG*2 - - 2 (.97) -
HHE/HHF*1 - 8 (2.31) - 2 (2.35)
HHF*1/HHG*1 - - - 1 (1.17)
HHF*1/HHG*2 - 2 (.58) - -
Total 62 (35.42) 118 (34.01) 54 (26.34) 35 (41.17)
Grand total 175 347 205 85
NOTE. DTH, delayed-type hypersensitivity; HH, human haplogroup; KLH, keyhole limpet hemocyanin; PPD, purified-protein derivative.
a CCR5 haplotype pairs (genotypes) based on the CCR5 promoter polymorphism at position –2459 (Figure 1) are shown. The single nucleotide polymorphism
(SNP) at –2135 is in 100% linkage with the SNP at the position –2459, such that –2459G is always linked with –2135T and –2459A is always linked with –2135C
(Figure 1). Therefore, for simplicity, only the CCR5 genotypes based on variations at position –2459 are shown.
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PPD) in healthy adults and clinical outcomes in 2 separate
cohorts of HIV-infected children. Our results demonstrate
a remarkable concordance in the CCR5 genotypes that asso-
ciated with DTH status in HIV-uninfected persons and those
that associated with disease progression rates. In the primary
Ukrainian cohort, 22459G/G- (Figure 2B), HHE/HHF*2-
(Figure 2D), and specific HHG*2 (D32)-containing genotypes
(Figure 3F) associated with disease retardation, and
apart from the D32-containing genotypes, these genotypes
also associated with increased DTH responses to KLH. By
contrast, HHE/HHG*2 and HHE/HHE associated with lower
DTH responses and a faster rate of disease progression in
Ukrainian children. Results from the replication cohorts,
underscored the beneficial impacts of 22459G/G on both
DTH and clinical outcomes (Figures 5 and 6). These results
lend credence to the notion that CCR5 may influence HIV
pathogenesis not only by impacting on parameters that are
dependent on its coreceptor activity (eg, HIV entry and viral
load), but also by influencing immune mechanisms (T cell
immunity).
DTH responses are sensitive in vivo indicators of the ability to
mount cell-mediated immune responses [1]. A distinctive aspect
of this study was that, to minimize potential confounding due to
variable prior exposure to these antigens, we applied the neo-
antigen KLH to healthy, HIV-uninfected adults [25]. In a sepa-
rate group of HIV-uninfected persons, we evaluated the DTH
responses to the recall antigen PPD. Thus, the use of a neo-
antigen is a strength of this study, and the results may further
our understanding of the genetic determinants of CMI, a highly
understudied area of research. Another strength of this study
was that we evaluated 2 separate HIV-infected cohorts for the
associations of CCR5 genotype with AIDS progression rates and
Figure 3. Association of CCR5 HHG*2 (D32)–containing genotypes with DTH responses to KLH (A, C, E) and rate of progression to AIDS (B, D, F) for
persons with the indicated CCR5 genotypes. A, C, and E, Boxplots are for data from all Australian participants with the indicated genotypes. Significance
values for all participants and the white persons in the Australian cohort are shown on the top. A and B, Comparisons are for participants bearing
the 22459G/G-containing genotypes (green), those bearing a CCR5-D32–containing HHG*2 haplotype (designated as G*2; blue), and the remaining
participants (designated as rest; red ). C and D, Comparisons are for participants who possess a D32-containing HHG*2 haplotype but differ according to
whether the HHG*2 haplotype is paired with the HHE haplotype (E/G*2; red) or a non-HHE haplotype (denoted as rest of G*2; green). E and F,
Comparisons are for participants who possessed a D32-containing HHG*2 haplotype but differed according to whether the HHG*2 haplotype was paired
with the HHC haplotype (C/G*2; orange), the HHE haplotype (E/G*2; red), or a haplotype other than HHC or HHE (denoted as rest of G*2; blue). B, D, and F,
P are log-rank or Wilcoxon significance values.
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found, in general, concordant associations between CCR5
genotype with both AIDS and DTH status.
We initiated our study by analyzing the association of CCR5
22459G/G, G/A, or A/A, because they have been scrutinized
extensively for several HIV and non-HIV phenotypes [27–31].
This afforded the opportunity to place the results obtained
herein the present study in the context of the following pre-
viously established genotype-phenotype correlations. First, re-
porter constructs bearing –2459G/–2135T (conflation of HHA
to HHD) have lower transcriptional activity than do those
bearing –2459A/–2135C (conflation of HHE to HHG) [8, 32].
Second, consistent with these transcriptional data, CCR5 re-
ceptor density on CD41 [9, 11] and CD141 monocytes [10, 11,
33] is lower in cells bearing CCR522459G/G than in the G/A or
A/A genotypes, with highest CCR5 expression in cells bearing
22459A/A. Third, concordant with the latter 2 associations and
consistent with the notion that CCR5 levels correlate with sus-
ceptibility to R5 virus infection [18], peripheral blood mono-
nuclear cells from healthy Caucasians bearing 22459G/G, A/G,
and A/A genotypes, respectively, associate with low, medium,
and high R5 viral propagation in vitro [10]. A concordant
hierarchy of R5 viral susceptibility was found after ex vivo
infection of Langerhans cells bearing 22459G/G, A/G, and A/A
genotypes [12]. Fourth, 22459G/G-containing genotypes
consistently associate with mitigated HIV and AIDS suscepti-
bility [7, 32, 34].
Consistent with the salutary associations for 22459G/G-
containing genotypes (reduced CCR5 transcriptional activity/
surface expression, viral replication, and HIV and AIDS sus-
ceptibility), we found that these genotypes associated not only
with HIV disease retardation but also enhanced DTH responses
in 2 HIV-uninfected cohorts. However, because of the differ-
ential distributions of CCR5 haplotypes across different human
populations [22], the associations of 22459G/G-containing
genotypes are likely to differ according to the ethnic/racial
background of the cohorts studied [7, 14].
After establishing the associations at the level of the 22459
(and linked 22135) SNP, we next identified the specific CCR5
haplotype pairs that influence DTH and AIDS status. The as-
sociations for the CCR5 haplotype pairs for HIV disease in the 2
pediatric cohorts are consistent with those reported previously
in adult HIV cohorts, and remarkably, in most instances, con-
cordant associations for these haplotype pairs were also observed
for DTH.
The data presented here, together with aforementioned
published data, affirm that the disease-retarding effects of
CCR5-D32 heterozygosity may be attributable mainly to 3 D32-
containing HHG*2 genotypes (HHA/HHG*2, HHC/HHG*2,
and HHF*2/HHG*2), whereas HHE/HHG*2 is associated with
Figure 4. Association of HHF*2 (CCR2-64I)–containing genotypes with
DTH responses to KLH (A, C) and rates of progression to AIDS (B, D).
Boxplots are shown for data from all Australian participants with the
indicated genotypes. A and B, Comparisons are for those possessing
HHE/HHF*2 (E/F*2) versus 2459G/G-containing genotypes. C and D,
Comparisons are for participants who possessed a CCR2-64I-containing
HHF*2 haplotype but differed according to whether the HHF*2 haplotype
was paired with the HHE haplotype (E/F*2; red) or a non-HHE haplotype
(denoted as rest of F*2; green). A and C, Significance values for all
participants and the white persons in the cohort are shown on the
top. B and D, P reflects Wilcoxon significance values.
Figure 5. Association of genotypes containing CCR5 22459G/G, G/A,
and A/A with DTH responses to purified-protein derivative (PPD) in HIV-
uninfected Colombians. This cohort represents a replication cohort to
assess the associations of DTH responses with CCR5 genotypes. Only
participants with an induration of.10 mm after application of PPD were
included in the analyses. A, Boxplots depicting DTH responses to PPD in
participants with genotypes containing CCR5 22459G/G (green),
22459G/A (blue), and 22459A/A (red). B, Participants bearing
22459A/A were further stratified into those 22459A/A genotypes that
are classified as HHE/HHE versus those 22459A/A genotypes that are
not HHE/HHE (designated as others; Table 1).
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detrimental effects. Of interest, the differentiating feature
of these protective versus detrimental CCR5-D32-containing
genotypes is whether the partner non-D32 haplotype is HHE.
These contrasting associations of specific D32-containing gen-
otypes should not be unexpected, because the functional burden
is placed entirely on the partner haplotype. The lower DTH
responses to KLH associated with the CCR5-D32 mutation is
consistent with the impaired responses to KLH in CCR5
knockout mice [4], and we surmise that this may relate to re-
duced leukocyte chemotaxis associated with this genotype [35].
The associations of HHE-containing genotypes also
underscore the importance of accounting for both CCR5 hap-
lotypes when conducting genotype-phenotype studies. Consis-
tent with prior reports [7, 13, 15], HHE/HHE associated with
disease acceleration in Ukrainian children, and we showed that it
also associates with reduced DTH responses to both KLH and
PPD. However, the association of HHE heterozygosity depends
on the partner allele, as exemplified by the observation that
HHE/HHF*2 (CCR2-64I) and HHE/HHG*2 (D32), re-
spectively, associated with higher versus lower CMI status and
with slow versus rapid disease progression.
CCR5 expression levels impact many different facets of HIV
pathogenesis, namely HIV entry [18, 19], HIV acquisition [7, 11,
19, 36], AIDS progression rates [37], viral load [37], immune
reconstitution during highly active antiretroviral therapy [37–
39], efficacy of CCR5 blockers and entry inhibitors [40], and
neutralizing activity of HIV-1–specific antibodies [41]. Re-
markably, in each instance, low CCR5 surface expression is as-
sociated with a protective phenotype. The prevailing viewpoint
links the beneficial effects of lower CCR5 expression to reduced
coreceptor activity of CCR5. However, we propose that CCR5
may also influence HIV pathogenesis by immune-based mech-
anisms independent of its function as a coreceptor. Support for
this thesis comes from several sources. First, extensive data now
indicate an important role for the CCR5-CCR5 ligand system in
T cell immunity, including formation of the immunological
synapse, T cell differentiation, proliferation, and activation-
induced cell death (discussed in [4, 17]). Relevant to this study,
CCR5 expression associates with Th1 responses, as do DTH
responses [1]. Second, nonhuman primates with simian im-
munodeficiency virus (SIV) infection that do not progress to
AIDS (eg, Sooty Mangabey) display low CCR5 levels, despite
high-level viremia [42], suggesting that the low CCR5 expression
may confer a protective effect by impacting on functions other
than viral entry, one of which we propose may be CMI status. Of
note, on the basis of its close homology to chimpanzee CCR5
sequence, HHA/HHA represents the ancestral genotype [8] and
is among the 22459G/G-containing genotypes that associated
with increased CMI status. In a previous study, we suggested that
this ancestral genotype may help to explain the partial resistance
to SIV disease progression in chimpanzee and the reduced ac-
quisition of SIV in some human populations that have a long
history of cohabitation with chimpanzees (eg, Pygmy) [14]. The
association of CCR5 HHA/HHA with increased CMI lends
further credence to this possibility. Third, the CCR5-null state or
antagonism of CCR5 is associated with reduced inflammation
and transplant rejection [17, 43, 44]. Furthermore, the impor-
tance of CCR5-associated CMI status is underscored by the
observation that22459G/G-containing genotypes correlate with
salutary effects in multiple other diseases in which the HIV-1
coreceptor activity of CCR5 is irrelevant [27–31].
Of note, CCR5 expression is correlated with T cell activation
levels [20, 45], and preseroconversion activation status predicts
both risk of infection and disease progression rates [46–50]. In
addition, preseroconversion CCR5 expression levels are a de-
terminant of disease progression [20]. Together, these
Figure 6. Replication of the associations of CCR5 G-2459A genotypes with progression to AIDS in a cohort of HIV-infected children from Argentina.
Kaplan-Meier plots for the association of the following CCR5 genotypes with rate of disease progression to AIDS: genotypes containing A, CCR5
22459G/G (green),22459G/A (blue), and22459A/A (red) ; B,22459G/G-containing genotypes (green), HHG*2-containing genotypes (G*2; red), and all
other genotypes (designated as rest ; blue); and C, D32-containing genotypes that contain HHE (E/G*2; red) versus all other D32-containing genotypes
(designated as rest of G*2; blue). P, log-rank significance values.
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observations raise the possibility that CCR5 genotypes influence
pre-infection status of CMI or other relevant immune pheno-
types (eg, T cell activation) that may alter both risk of infection
and AIDS progression rates.
In summary, we found a high degree of concordance between
the associations of CCR5 genotypes that influence DTH status
and those that influence CCR5 transcriptional activity and/or
surface expression, viral replication, and HIV and AIDS sus-
ceptibility. These data support 2 related conclusions. First, they
indicate a genetically determined relationship among reduced
CCR5 expression, increased CMI responses, reduced HIV rep-
lication, and disease retardation. Second, CCR5 may affect HIV
and AIDS susceptibility by influencing 2 different mechanisms:
1) viral entry and/or replication and 2) CMI.
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